Printer Friendly

Zila issued additional patent related to the OraTest oral cancer detection product.

Zila, Inc. (Phoenix, AZ; 602-266-6700), international provider of healthcare products for dental/medical professionals and consumers, announced that the United States Patent and Trademark Office has issued the company a patent covering the use of a wide range of dyes for the detection of oral cancer. Zila already holds several patents and has additional patent applications pending for the use of a specific dye, toluidine blue 0, or tolonium chloride, for the detection of oral cancer. These patents are connected with Zila's oral cancer detection product, OraTest. The new patent covers the use of the oxadine and thiazine classes of dyes in detecting cancer by direct application to the oral tissues. (Toluidine blue O is a member of the thiazine class).

Dr. Ralph Green, president of Zila Biomedical, said, "Our action in securing this new patent is simply to provide protection so that no competitor can emerge with an alternate dye from the same or a comparable chemical family. Several years ago, therefore, Zila filed patent applications in appropriate countries, claiming the use of oxadine and thiazine classes of dyes in general."

Zila markets products and services to professionals and consumers through three operating groups. The Pharmaceuticals/Biomedical Group includes: Zila Pharmaceuticals, marketer of prescription and non-prescription oral healthcare products; Zila Biomedical, introducing the OraTest oral cancer detection product worldwide; and Zila Manufacturing, producer of the only pharmaceutical-grade toluidine blue - Zila Tolonium Chloride. The Professional Products Group includes: Cygnus Imaging, manufacturer and marketer of intraoral video camera and digital X-ray systems; Zila Dental Supply, a national dental supplies distributor; and PracticeWorks, developer and marketer of proprietary dental practice management software. The Nutraceuticals Group includes Oxycal Laboratories and its Inter-Cal subsidiary, manufacturer and supplier of patented Ester-C vitamin products worldwide.
COPYRIGHT 1999 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Zila issued additional patent related to the OraTest oral cancer detection product.
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Mar 1, 1999
Words:289
Previous Article:Genzyme Transgenics and Millennium BioTherapeutics collaborate to develop transgenic therapeutic proteins and antibodies.
Next Article:Aquasearch awarded United States patent for process of astaxanthin-producing microalgae.
Topics:


Related Articles
Zila to market OraTest in Republic of China.
Zila has "Productive" OraTest Meeting with FDA.
Zila's OraTest Oral Cancer Detection System Approved in Several European Union Nations.
Zila's Oral Cancer Detection System Launched in UK.
Zila Licenses Oratest Oral Cancer Detection System to Japanese Healthcare Giant, Nippon Shoji Kaisha.
OraTest now available in Greece.
ZILA REPORTS HIGHER NET REVENUES FOR 3RD QTR FISCAL '02.
ZILA REPORTS 20.7 PERCENT INCREASE IN REVENUE.
ZILA REPORTS 36% REVENUE GROWTH FOR FISCAL 2ND QTR.
ZILA FISCAL 2005 2ND QTR NET REVENUES DECREASE 2%.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters